The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pericarditis (see also under XIIc)
Publications
Incessant pericarditis following the second dose of SARS-CoV-2 mRNA vaccine successfully treated with anakinra: a case report.
European heart journal. Case reports 2022 Sep;6;ytac357 — 2022 Sep — ytac357
Acute Pericarditis Post mRNA-1273 COVID Vaccine Booster.
Cureus 2022 Feb;14;e22148 — 2022 Feb — e22148
Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines.
Cureus 2021 Jun;13;e15576 — 2021 Jun — e15576
Covid-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines?
BMJ (Clinical research ed.) 2021 Jun 24;373;n1635 — 2021 Jun 24 — n1635
Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, Zisapel M, Elalouf O, Kaufman I, Meidan R, Broyde A, Polachek A, Wollman J, Litinsky I, Meridor K, Nochomovitz H, Silberman A, Rosenberg D, Feld J, Haddad A, Gazzit T, Elias M, Higazi N, Kharo
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
Annals of the rheumatic diseases 2021 Jun 14;; — 2021 Jun 14